Cullinan Therapeutics (CGEM) EBITDA Margin (2021)
Cullinan Therapeutics (CGEM) has 1 years of EBITDA Margin data on record, last reported at 0.68% in Q1 2021.
- For Q1 2021, EBITDA Margin changed N/A year-over-year to 0.68%; the TTM value through Dec 2021 reached 350.56%, changed N/A, while the annual FY2021 figure was 350.56%, N/A changed from the prior year.
- EBITDA Margin reached 0.68% in Q1 2021 per CGEM's latest filing.
- Across five years, EBITDA Margin topped out at 0.68% in Q1 2021 and bottomed at 0.68% in Q1 2021.